Vitiligo: Analysis of grafting versus curettage alone, using melanocyte morphology and reverse transcriptase polymerase chain reaction for tyrosinase mRNA

Sao Paulo Medical Journal

Volumn 123, Issue 4, 2005, Pages 187-191

  dos Santos Machado Filho, Carlos D'Aparecida ^a   Almeida, Fernando Augusto ^b   Proto, Rodrigo Sestilo ^a   Landman, Gilles ^a,c  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Med Res Center Hospital do Cancer   (Brazil)

Author keywords

Pathology; Polymerase chain reaction; Transplants; Tyrosinase; Vitiligo

Indexed keywords

MESSENGER RNA; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BRAZIL; CELL ACTIVATION; CELL STIMULATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MELANOCYTE; POSTOPERATIVE PERIOD; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SKIN BIOPSY; SKIN TRANSPLANTATION; TREATMENT OUTCOME; VITILIGO;

EID: 26044448081     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802005000400006     Document Type: Article

References (30)

1. Pawelek JM. After dopachrome? Pigment Cell Res. 1991;4(2):53-62.
2. Breathnach AS, Bor S, Wyllie LM. Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo. J Invest Dermatol. 1966;47(2):125-40.
3. Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch. Dermatol. 1999;135(4):417-22.
4. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol. 1998;111(6):1034-9
5. Bartosik J, Wulf HC, Kobayasi T. Melanin and melanosome complexes in long standing stable vitiligo - an ultrastructural study. Eur J Dermat. 1998;8(2):95-7.
6. Galadari E, Mehregan AH, Hashimoto K. Ultrastructural study of vitiligo. Int J Dermatol. 1993;32(4):269-71.
7. Le Poole IC, van den Wijngaard RM, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol. 1993;100-(6):816-22.
8. Hirobe T. Structure and function of melanocytes: microscopic morphology and cell biology of mouse melanocytes in the epidermis and hair follicle. Histol Histopathol. 1995;10(1):223-37.
9. Blaheta HJ, Schittek B, Breuninger H, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol. 1999;23(7):822-8.
10. Ortonne JP, MacDonald DM, Micoud A, Thivolet J. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. British J Dermatol. 1979;101(1):1-12.
11. Chakrabarti SG, Grimes PE, Minus HR, Kenney JA Jr, Pradhan TK. Determination of trimethylpsoralen in blood, ophthalmic fluids, and skin. J Invest Dermatol. 1982;79(6):374-7.
12. Urbanek RW. Tar vitiligo therapy. J Am Acad Dermatol. 1983;8(5):755.
13. Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. Arch Dermatol. 1999;135(2):216-7.
14. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology. 1998;197(2):167-70.
15. Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by UVB-activated pseudocatalase. J Investig Dermatol Symp Proc. 1999;4(1):91-6.
16. Koga M. Vitiligo: a new classification and therapy. Br J Dermatol. 1977;97(3):255-61.
17. Vasistha LK, Singh G. Vitiligo and intralesional steroids. Indian J Med Res. 1979;69:308-11.
18. Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol. 1983;22(8):477-80.
19. Tsuji T, Hamada T. Topically administered fluorouracil in vitiligo. Arch Dermatol. 1983;119(9):722-7.
20. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol. 1977;97(6):669-79.
21. Orentreich N. Autografts in alopecias and other selected dermatological conditions. Am N Y Acad Sci. 1959;83:463-79.
22. Bonafe JL, Lassere J, Chavoin JP, Baro JP, Jeune R. Pigmentation induced in vitiligo by normal skin grafts and PUVA stimulation: a preliminary study. Dermatologica. 1983;166(3):113-6.
23. Malakar S, Dhar S. Repigmentation of vitiligo patches by transplantation of hair follicles. Int J Dermatol. 1999;38(3):237-38.
24. Andreassi L, Pianigiani E, Andreassi A, Taddeucci P, Biagioli M. A new model of epidermal culture for the surgical treatment of vitiligo. Int J Dermatol. 1998;37(8):595-8.
25. Njoo MD, Das PK, Bos JD, Westerhof W. Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407-13.
26. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Mohler T, Hunstein W. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol. 1993;101(6):887-9.
27. Naeyaert JM, Eller M, Gordon PR, Park HY, Gilchrest BA. Pigment content of cultured human melanocytes does not correlate with tyrosinase message level. Br J Dermatol. 1991;125(4):297-303.
28. Abdel-Malek Z, Swope VB, Suzuki I, et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A. 1995;92(5):1789-93.
29. Archambault M, Yaar M, Gilchrest BA. Keratinocytes and fibroblasts in a human skin equivalent model enhance melanocyte survival and melanin synthesis after ultraviolet irradiation. J Invest Dermatol. 1995;104(5):859-67.
30. Horikawa T, Norris DA, Yohn JJ, Zekman T, Travers JB, Morelli JG. Melanocyte mitogens induce both melanocyte chemokinesis and chemotaxis. J Invest Dermatol. 1995;104(2):256-9.